What this means
This is a planned study that will compare daily avocados with a usual diet. It has not finished, so it cannot yet tell us whether avocados affect aging.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 40–65 · 120 breast cancer survivors
- Where
- 1 site
The science
- Registered title
- Avocado Consumption and Cellular Aging in Breast Cancer Survivors
- Trial ID
- NCT07097155 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Telomere Length, Breast Cancer Females
- What is tested
- Daily Avocado Consumption
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
- Ages
- 40 Years to 65 Years
- Dates
- First posted Jul 31, 2025 · updated May 12, 2026
Registry summary
Women with breast cancer are at increased risk of comorbidities and premature mortality, potentially due to accelerated biological aging. Telomere attrition has been proposed as a biomarker of this process, which could be mitigated through interventions targeting behavioral factors such as diet. In recent years, avocado has drawn attention in nutritional research due to its unique nutritional profile.
Main objective: To evaluate the effect of consuming one avocado per day on biological aging-measured by telomere length-in breast cancer survivors, compared to a habitual diet (less than two avocados per week). Secondary objectives include changes in telomerase activity and biomarkers of inflammation and oxidative stress. Additional objectives include classical cardiovascular disease markers (glucose metabolism, lipid profile, blood pressure); anthropometric measurements; symptoms of depression and anxiety; quality of life and fatigue; and diet quality.
Methodology: A randomized controlled parallel-group trial involving 120 breast cancer survivors. Participants will be randomly assigned to either the intervention group (one avocado per day) or the control group (habitual diet with fewer than two avocados per week) and followed for 4 months. At baseline and the end of the intervention, a general questionnaire will be administered; blood and urine samples will be collected; anthropometric and blood pressure measurements will be taken; and diet, physical activity, symptoms of depression and anxiety, quality of life, and fatigue will be assessed. Mean changes from baseline to the end of the intervention in the primary outcome (telomere length) and secondary outcomes (inflammation, oxidative stress, classical cardiovascular disease markers, anthropometric measures, symptoms of depression and anxiety, quality of life, and diet) will be compared between the intervention and control groups using linear regression models.
Sites (1)
- Unit for Public Health and Nutritional Epidemiology, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, Tarragona, Spain
